Showing results (2151-2160 of 8,963) with videos related to
Sort By:
Pageof 897
Journal of Hepatology|August 1, 1993
Measuring lidocaine metabolite--monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosisY S Huang, S D Lee, J F Deng, et al.Journal of Hepatology|July 6, 2026
Ivonescimab plus gemcitabine and cisplatin as first-line therapy for advanced biliary tract cancer: a multicenter, open-label phase 2 trialQi Xu, Shurui Zhou, Chenbo Zhang, et al.Journal of Hepatology|July 5, 2026
Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: primary results from the phase IIIb TOURMALINE studyDo-Youn Oh, Masafumi Ikeda, Teresa Macarulla, et al.Journal of Hepatology|June 18, 2026
Interleukin-19 ameliorates drug-induced liver injury by limiting proinflammatory macrophage infiltration via SUMOylation of C/EBPβPeng Xiao, Qiuhong Zai, Ningning Ma, et al.Journal of Hepatology|March 1, 1989
The histoautoradiographic localization of taurocholate in rat liver after bile duct ligation. Evidence for ongoing secretion and reabsorption processesH P Buscher, C Miltenberger, S MacNelly, et al.Journal of Hepatology|September 1, 1991
The acinar location of the sodium-independent and the sodium-dependent component of taurocholate uptake. A histoautoradiographic study of rat liverH P Buscher, U Schramm, S MacNelly, et al.Journal of Hepatology|July 1, 1989
Taurocholate increases the biliary output of bilirubin pigments in the rat, due to haemolysisV A Mesa, J De Groote, J FeveryJournal of Hepatology|June 24, 2026
Regression of liver cirrhosisJonathan Andrew Fallowfield, Prakash Ramachandran, Timothy James KendallJournal of Hepatology|January 24, 2004
Chronic inhibition of nitric oxide increases the collateral vascular responsiveness to vasopressin in portal hypertensive ratsHui-Chun Huang, Sun-Sang Wang, Che-Chang Chan, et al.Journal of Hepatology|July 16, 2026
A machine learning approach to non-invasive prediction of hepatic decompensation in compensated advanced chronic liver disease: the CIRI modelGeorg Kramer, Anders Hildeman, Caterina Tozzi, et al.Pageof 897